James Quigley
Stock Analyst at Morgan Stanley
(0.93)
# 3,725
Out of 4,876 analysts
22
Total ratings
66.67%
Success rate
-14.45%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $44.11 | +79.10% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $47.86 | +35.81% | 1 | Mar 21, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $119.70 | +1.09% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.85 | +18.64% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $27.87 | +43.55% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.19 | +281.86% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $44.11
Upside: +79.10%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $47.86
Upside: +35.81%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $119.70
Upside: +1.09%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.85
Upside: +18.64%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $27.87
Upside: +43.55%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.19
Upside: +281.86%